Acurian, Onconova sign Clinical Trial Liaison Services agreement

Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, announced today that it has signed an agreement with Onconova Therapeutics®, Inc., a private biopharmaceutical company located in Newtown, PA and Pennington, NJ.

Acurian will provide Clinical Trial Liaison Services (CTL) as city-specific resources. CTLs have deep practical oncology knowledge and research-specific experience. They will provide Onconova with referral physician support within the surrounding area of clinical investigators for the "ONTIME" trial (ON 01910.Na Trial in Myelodysplastic Syndrome), which is now being conducted in more than 50 sites in the U.S. and Europe.

ONTIME is presently recruiting patients across the U.S. and the Acurian CTLs will assist with area Hematology/Oncology awareness of ONTIME across five cities. These highly experienced professionals work among local community and institutional practices to raise overall trial awareness, and to build relationships with local physicians, advocacy groups, tumor boards, and medical and nursing societies.

"Acurian is grateful for this opportunity to assist Onconova with the ONTIME trial. Our CTLs will support this important assignment to the benefit of healthcare providers and patients with MDS," said Edwin Watson, Senior Director, Oncology at Acurian. "We are aware that only three percent of cancer patients in the United States participate in oncology trials, while many may benefit from expanded participation," he added.